Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 12, 2024

SELL
$17.71 - $32.97 $58,124 - $108,207
-3,282 Reduced 22.37%
11,389 $359,000
Q3 2023

Nov 13, 2023

BUY
$25.44 - $37.35 $131,372 - $192,875
5,164 Added 54.32%
14,671 $374,000
Q2 2023

Aug 14, 2023

BUY
$23.94 - $32.36 $227,597 - $307,646
9,507 New
9,507 $272,000
Q4 2021

Feb 10, 2022

SELL
$34.2 - $47.56 $159,474 - $221,772
-4,663 Closed
0 $0
Q3 2021

Oct 28, 2021

SELL
$27.88 - $58.25 $181,247 - $378,683
-6,501 Reduced 58.23%
4,663 $223,000
Q2 2021

Aug 10, 2021

BUY
$25.79 - $42.11 $12,895 - $21,055
500 Added 4.69%
11,164 $378,000
Q1 2021

Jul 21, 2021

BUY
$38.75 - $86.92 $413,230 - $926,914
10,664 New
10,664 $440,000

Others Institutions Holding ARCT

About Arcturus Therapeutics Holdings Inc.


  • Ticker ARCT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 26,576,400
  • Market Cap $439M
  • Description
  • Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lun...
More about ARCT
Track This Portfolio

Track Winton Group LTD Portfolio

Follow Winton Group LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Winton Group LTD, based on Form 13F filings with the SEC.

News

Stay updated on Winton Group LTD with notifications on news.